08/30/2010 Achaogen Awarded Contract Worth up to $64 Million by BARDA for the Development of ACHN-490
- Achaogen has Raised More Than $150 Million in Non-Dilutive Funding -

07/19/2010 Xconomy: Achaogen, Flush with $56M, Seeks to Build Lasting Company with Potent Antibiotics
Luke Timmerman
Xconomy
July 19, 2010
Read more...

04/07/2010 Achaogen Completes $56 Million Series C Financing
-Proceeds Will Continue to Advance Clinical Development of Novel Antibiotics to Combat Multi-Drug Resistant Gram-Negative Bacteria and MRSA-

09/14/2009 Achaogen Announces ACHN-490 Clinical Data at the 49th Annual ICAAC Meeting

-Achaogen’s Neoglycoside Shown to be Well-Tolerated in Phase 1, Dose-Ranging Clinical Trial-
-Additional Preclinical Data Validates ACHN-490’s Consistent Activity Against Gram-Negative and Aminoglycoside-Resistant Bacteria-

08/25/2009 Achaogen Appoints John C. Doyle to the Newly Created Position of Chief Operating Officer
Achaogen announced today the appointment of John C. Doyle to the newly created position of chief operating officer.

08/01/2009 Betting the Pharma
"ACHAOGEN: SUPERBUG SWATTER  |  This San Francisco biotech is developing a new antibiotic arsenal against the growing global superbug crisis, including methicillin-resistant Staphylococcus aureus (MRSA) and Gram-negative bacteria."
Walter Armstrong
PharmaExec
August 1, 2009
Read more...

06/30/2009 FierceBiotech Names Achaogen as One of the “Fierce 15" Biotech Companies of 2009
Achaogen announced today that it has been selected as one of the annual FierceBiotech “Fierce 15” list, designating it as one of the top biotech companies of 2009.

06/29/2009 Achaogen Named One Of 2009 "Fierce 15" Biotechnology Companies
FierceBiotech
June 29, 2009
Read more...

05/16/2009 Achaogen Data Show Rapid Rise in Rates of Resistance to Current Antibiotics; Illustrate Global Need for New, Well-Tolerated Agents to Address Varied Mechanisms of Resistance
- Data Presented at European Congress of Clinical Microbiology and Infectious Diseases -

03/23/2009 Achaogen Selected to Present at InsideVenture’s Debut Investor Conference
- March 25-26, Santa Barbara, California -

03/10/2009 Achaogen to Present at Cowen and Company 29th Annual Health Care Conference

03/03/2009 Achaogen Signs $26.6 Million Contract with NIAID for Development of New Therapy to Treat Resistant Strains of NIAID Category A and B Priority Pathogens
This award will fund the discovery and development of proprietary Achaogen compounds to combat biothreat strains of Gram-negative bacteria such as Yersinia pestis, the causative agent of bubonic plague, and Francisella tularensis, the causative agent of tularemia.

02/03/2009 Biotechs Befriend Non-Dilutive Funds
The Wall Street Journal: Venture Capital Dispatch
February 3, 2009
Read more...

02/03/2009 Achaogen Initiates Phase 1 Trial of ACHN-490 for Treatment of Multi-Drug Resistant Gram-Negative Bacterial Infections
- Trial Initiation Marks Company’s First Neoglycoside to Enter Clinic -

01/30/2009 Achaogen Inc. takes aim at superbugs
San Francisco Business Times
January 30, 2009
Read more...

01/08/2009 Achaogen Receives ₤4.1 Million Award from the Wellcome Trust to Advance its Neoglycosides Portfolio
This award will help support the investigational new drug (IND)-enabling studies and advancement into clinical trials of Achaogen’s portfolio of proprietary neoglycosides for the treatment of Gram-negative bacterial infections.

12/17/2008 Achaogen Appoints Thomas B. King and Christopher T. Walsh to Board of Directors
Achaogen announced today the appointments of Thomas B. King, President and Chief Executive Officer of Alexza Pharmaceuticals (NASDAQ: ALXA), and Christopher T. Walsh, Ph.D., the Hamilton Kuhn Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School, to its Board of Directors.

10/29/2008 Bad Bug Busters
"Silicon Valley firm, Achaogen, believes it can win the battle against drug-resistant bacteria."
Forbes.com Video Network
October 29, 2008
Visit Forbes.com...

10/24/2006 Achaogen Awarded $24.7M Biodefense Contract by DTRA
Four-year contract funds preclinical development of therapies to combat anthrax, plague...

10/10/2006 Achaogen Closes Series B Financing
Achaogen announced today that it has closed its Series B round of financing, raising over $26 million dollars...